



1631
SOCKET NO.: ISIS-3455

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAY 19 2003
TECH CENTER 1600/2900

In Re Application of:

Lex M. Cowsert, et al.

Confirmation No.: 7206

Application No.: 09/295,463

Group Art Unit: 1631

Filing Date: April 13, 1999

Examiner: Ardin H. Marschel

**For: IDENTIFICATION OF GENETIC TARGETS FOR MODULATION BY
OLIGONUCLEOTIDES AND GENERATION OF OLIGONUCLEOTIDES
FOR GENE MODULATION**

DATE OF DEPOSIT: *May 13, 2003*

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE COMMISSIONER FOR PATENTS,
P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Elizabeth A. McLoud
TYPE NAME: Elizabeth A. McLoud

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).



In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith


EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☐ Copies of references **[list as appropriate]** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. , filed .
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: *May 13, 2003*


Daniel D. Biesterveld
Registration No. 45,898

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Sheet 1 of 2

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-3455	Application No. 09/295,463
		Applicant Lex M. Cowsert, et al.	
		Filing Date April 13, 1999	Group 1631
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	249	DeCamp, D., et al., "Site-directed drug design," <i>Protein Engineering, Principles and Practice</i> , Cleland, J.L., et al. (Eds.), 1996 , Chapter 17, 467-472	
	250	Genome Analysis – A Laboratory Manual, "Analyzing DNA," 1997 , Vol. 1, 574-578	
	251	Lomakin, A., et al., "A theoretical analysis of specificity of nucleic acid interactions with oligonucleotides and peptide nucleic acids (PNAs)," <i>J. Molecular Biology</i> , February 13, 1998 , 276(1), 1-24	
EXAMINER		DATE CONSIDERED	

**Form PTO-1449 Modified**

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.
ISIS-3455

Application No.
09/295,463

Applicant
Lex M. Cowsert, et al.

Filing Date
April 13, 1999

Group
1631

RECEIVED
MAY 19 2003
TECH CENTER 1600/2900

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	252	4,800,159	01/24/89	Mullis, et al.	435	172.3
	253	5,697,248	12/16/97	Brown, et al.	73	290
	254	5,783,431	07/21/98	Peterson, et al.	435	172.3
	255	5,856,101	01/05/99	Hubbell, et al.	435	6
	256	5,859,221	01/12/99	Cook, et al.	536	23.1
	257	5,955,589	09/21/99	Cook, et al.	536	23.1

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO

EXAMINER**DATE CONSIDERED**